Vivan Therapeutics Announces the Appointment of Lilly Wollman to Its Board of Directors

My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a global leader in personalised cancer therapeutics and in-vivo high throughput drug screening, is pleased to announce the addition of Lilly Wollman to its distinguished board of directors.

Lilly Wollman is a seasoned team-builder and entrepreneurial leader with a 20-year track record in finance and investing. Currently, she is pursuing an MPhil in Computational Biology from the University of Cambridge and is dedicated to a second career solving complex problems in human health through the application of data science and machine intelligence. She is currently a research intern in the CRUK Early Detection Programme and at the Milner Therapeutics Institute.

Recommended AI News: Amalgam Rx Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets

Previously, she was in a leadership position at the foremost sustainability investment firm as partner and co-head of the Growth Equity platform for Generation Investment Management, the $25 billion investment firm founded by Al Gore and David Blood. She was responsible for the firm’s investments in early-stage technology companies driving a transition to a sustainable economy and led a team of 20 individuals across the London and San Francisco offices. Lilly served as a member of the Board of Directors of Labstep, Sophia Genetics, Andela and Cibo Technologies.

Before Generation, Lilly held investment roles at The Baupost Group, and Fortress Investment Group, where she worked in the special opportunities fund. Lilly started her career at Goldman Sachs in the Fixed Income, Currency and Commodities Division.

Lilly graduated magna cum laude and Phi Beta Kappa from Dartmouth College with a BA in Mathematics and a minor in Classics. She received her MBA from INSEAD and her MSc in Finance from London Business School.

Recommended AI News: Numonix IXCloud Certified as Microsoft Teams Solution

Vivan Therapeutics’ platform technology, the Personal Discovery Process, was developed at the Icahn School of Medicine at Mount Sinai, N.Y., and is now being used to provide treatment insights to patients and their clinicians. The Personal Discovery Process is a unique platform that enables screening of a vast array of molecules and combinations in disease-relevant patient models. Its growing data enables efficacy studies, evaluation of combinations, competitive profiling and rapid virtual clinical studies across numerous disease-relevant in-vivo models or custom-designed models.

“I’m grateful for Lilly’s contributions to Vivan’s strategic growth to date and welcome Lilly’s vast industry experience and leadership in helping us plot the course of our future development,” said Laura Towart, CEO of Vivan Therapeutics.

Lilly Wollman commented, “I am delighted to join the board of Vivan Therapeutics. Vivan is the only in-vivo cancer treatment modeling platform, uniquely capable of delivering high-throughput, personalised and combination therapy insights to medical practitioners, biopharma, and to aid drug discovery. With its focus on integrating machine learning and predictive toxicological screening, Vivan has the opportunity to dramatically reduce the time and cost of treatment and discovery for the benefit of patients and the life sciences ecosystem.”

Recommended AI News: Numenta Demonstrates 100x Performance Acceleration in Deep Learning Networks Using Sparse Techniques